Terns Pharmaceuticals Inc. (TERN) Begins Dosing in Phase 1 Clinical Trial of TERN-501

Go back to Terns Pharmaceuticals Inc. (TERN) Begins Dosing in Phase 1 Clinical Trial of TERN-501
(NASDAQ: TERN) Delayed: 16.21 -0.16 (0.98%)
Previous Close $16.37    52 Week High
Open $16.73    52 Week Low
Day High $17.00    P/E N/A 
Day Low $16.05    EPS
Volume 36,132